scholarly journals TBX2 expression is associated with platinum‑sensitivity of ovarian serous carcinoma

2017 ◽  
Author(s):  
Reiko Tasaka ◽  
Takeshi Fukuda ◽  
Masahiro Shimomura ◽  
Yuta Inoue ◽  
Takuma Wada ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma ◽  
Platinum Sensitivity ◽  
Tbx2 Expression

β-catenin nuclear localization is associated with grade in ovarian serous carcinoma

2003 ◽  
Vol 88 (3) ◽  
pp. 363-368 ◽  
Author(s):  
Christine M Lee ◽  
Hyun Shvartsman ◽  
Michael T Deavers ◽  
Shao-Chun Wang ◽  
Weiya Xia ◽  
...  
Keyword(s):  
Nuclear Localization ◽  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma

scholarly journals Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages

2016 ◽  
Vol 17 (6) ◽  
pp. 886 ◽  
Author(s):  
Chia-Ming Chang ◽  
Chi-Mu Chuang ◽  
Mong-Lien Wang ◽  
Ming-Jie Yang ◽  
Cheng-Chang Chang ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma ◽  
Gene Set ◽  
Molecular Features

scholarly journals Highly Expressed Progesterone Receptor B Isoform Increases Platinum Sensitivity and Survival of Ovarian High-Grade Serous Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5578
Author(s):  
Hao Lin ◽  
Kuo-Chung Lan ◽  
Yu-Che Ou ◽  
Chen-Hsuan Wu ◽  
Hong-Yo Kang ◽  
...  
Keyword(s):  
Progesterone Receptor ◽  
Cell Model ◽  
Serous Carcinoma ◽  
Survival Outcomes ◽  
High Grade ◽  
Cancer Specific Survival ◽  
Platinum Sensitivity ◽  
Platinum Sensitive ◽  
Resistant Disease ◽  
Cisplatin Sensitivity

Background: Expression of the progesterone receptor (PR) has been reported to influence survival outcomes in patients with ovarian high-grade serous carcinoma (HGSC). In the present study, we attempted to investigate the association among PR and its isoforms’ expression, platinum sensitivity, and survival in ovarian HGSC. Material and methods: This retrospective study reviewed ovarian HGSC patients who received surgery followed by adjuvant chemotherapy. We analyzed total PR and PR isoform-B (PR-B) expression by immunohistochemical staining and quantified using the H-score. Then, we compared platinum sensitivity and survival outcomes between those patients with weak and strong PR-B expression. Cisplatin viability assays were carried out in ovarian HGSC cell lines (OC-3-VGH and OVCAR-3) with different PR-B expression. Results: Among 90 patients, 49 and 41 patients were considered to have platinum-sensitive and platinum-resistant disease, respectively. Pearson’s correlation model showed that the H-score of total PR correlated positively with PR-B (r = 0.813). The PR-B H-score of tumors was significantly higher in the platinum-sensitive group (p = 0.004). Multivariate analysis revealed that the PR-B H-score and optimal debulking status were independent factors predicting platinum sensitivity. When compared with strong PR-B expression, patients with weak PR-B had significantly poorer progression-free (p = 0.021) and cancer-specific survival (p = 0.046). In a cell model, cisplatin-resistant OC-3-VGH cells expressed a lower level of PR-B than wild-type cells. Overexpression of PR-B or progesterone could increase cisplatin sensitivity in both OC-3-VGH and OVCAR-3 cells via the mechanism of promoting cisplatin-related apoptosis. Conclusions: When compared to weak PR-B, ovarian HGSC patients with a strong PR-B expression had a better chance of platinum sensitivity and survival, and this finding was compatible with our experimental results. Progesterone seemed to be a platinum sensitizer, but the value of adding progesterone in the treatment of ovarian HGSC should be further investigated.

scholarly journals Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma

2018 ◽  
Author(s):  
Yunfeng Jin ◽  
Yi Zou ◽  
Linling Wan ◽  
Mingming Lu ◽  
Ya Liu ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma ◽  
Eph Receptor

Should All Cases of High-Grade Serous Ovarian, Tubal, and Primary Peritoneal Carcinomas Be Reclassified as Tubo-Ovarian Serous Carcinoma?

2015 ◽  
Vol 25 (7) ◽  
pp. 1201-1207 ◽  
Author(s):  
Esther Louise Moss ◽  
Tim Evans ◽  
Philippa Pearmain ◽  
Sarah Askew ◽  
Kavita Singh ◽  
...  
Keyword(s):  
Overall Survival ◽  
Clear Cell ◽  
Stage Iii ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Type I ◽  
High Grade ◽  
Type Ii ◽  
Ovarian Serous Carcinoma ◽  
Significant Difference

IntroductionThe dualistic theory of ovarian carcinogenesis proposes that epithelial “ovarian” cancer is not one entity with several histological subtypes but a collection of different diseases arising from cells of different origin, some of which may not originate in the ovarian surface epithelium.MethodsAll cases referred to the Pan-Birmingham Gynaecological Cancer Centre with an ovarian, tubal, or primary peritoneal cancer between April 2006 and April 2012 were identified from the West Midlands Cancer Registry. Tumors were classified into type I (low-grade endometrioid, clear cell, mucinous, and low-grade serous) and type II (high-grade serous, high-grade endometrioid, carcinosarcoma, and undifferentiated) cancers.ResultsOvarian (83.5%), tubal (4.3%), or primary peritoneal carcinoma (12.2%) were diagnosed in a total of 583 woman. The ovarian tumors were type I in 134 cases (27.5%), type II in 325 cases (66.7%), and contained elements of both type I and type II tumors in 28 cases (5.7%). Most tubal and primary peritoneal cases, however, were type II tumors: 24 (96.0%) and 64 (90.1%), respectively. Only 16 (5.8%) of the ovarian high-grade serous carcinomas were stage I at diagnosis, whereas 240 (86.6%) were stage III+. Overall survival varied between the subtypes when matched for stage. Stage III low-grade serous and high-grade serous carcinomas had a significantly better survival compared to clear cell and mucinous cases,P= 0.0134. There was no significant difference in overall survival between the high-grade serous ovarian, tubal, or peritoneal carcinomas when matched for stage (stage III,P= 0.3758; stage IV,P= 0.4820).ConclusionsType II tumors are more common than type I and account for most tubal and peritoneal cancers. High-grade serous carcinomas, whether classified as ovarian/tubal/peritoneal, seem to behave as one disease entity with no significant difference in survival outcomes, therefore supporting the proposition of a separate classification of “tubo-ovarian serous carcinoma”.

Grading Ovarian Serous Carcinoma Using a Two-Tier System

2004 ◽  
Vol 28 (4) ◽  
pp. 496-504 ◽  
Author(s):  
Anais Malpica ◽  
Michael T Deavers ◽  
Karen Lu ◽  
Diane C Bodurka ◽  
Edward N Atkinson ◽  
...  
Keyword(s):  
Serous Carcinoma ◽  
Ovarian Serous Carcinoma ◽  
Tier System
Sign in / Sign up

Export Citation Format

Share Document